Convergence Investment Partners, LLC Ligand Pharmaceuticals Inc Transaction History

Convergence Investment Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 13, 2019	SELL	$128.36 - $272.13 $318,332 - $674,882	-2,480 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$211.18 - $274.49 $987,688 - $1.28 Million	-4,677 Reduced 65.35%	2,480 $681,000
Q2 2018 Aug 07, 2018	SELL	$150.77 - $207.98 $558,904 - $770,981	-3,707 Reduced 34.12%	7,157 $1.48 Million
Q1 2018 May 14, 2018	SELL	$138.63 - $182.62 $533,448 - $702,721	-3,848 Reduced 26.16%	10,864 $1.79 Million
Q4 2017 Jan 16, 2018	BUY	$128.36 - $147.04 $155,315 - $177,918	1,210 Added 8.96%	14,712 $2.02 Million
Q3 2017 Nov 13, 2017	BUY	$120.91 - $137.94 $1.63 Million - $1.86 Million	13,502	13,502 $1.84 Million

257

18.2M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.01B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Convergence Investment Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Convergence Investment Partners, LLC with notifications on news.